Annual report pursuant to Section 13 and 15(d)

Quarterly Results (Unaudited) - Schedule of Quarterly Financial Data (Details)

v3.8.0.1
Quarterly Results (Unaudited) - Schedule of Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]                        
Research and development $ 1,103 $ 1,393 $ 1,255 $ 2,071 $ 93,876 [1] $ 2,093 $ 2,368 $ 3,342 $ 38,700 $ 5,822 $ 101,679 $ 47,261
General and administrative 728 717 (55) 1,050 510 (199) 1,836 1,992   2,440 4,140 6,765
Total costs and expenses 1,831 2,110 1,200 3,121 94,386 1,894 4,204 5,334   8,262 105,819 54,026
Operating loss (1,831) (2,110) (1,200) (3,121) (94,386) (1,894) (4,204) (5,334)   (8,262) (105,819) (53,948)
Other income (expense), net (152) 150 198 573 (762) 13 977 1,322        
Income tax benefit 6,880 29,394   (6,880) (29,394) (15,248)
Net (loss) income $ 4,897 $ (1,960) $ (1,002) $ (2,548) $ (65,754) $ (1,881) $ (3,227) $ (4,012)   $ (613) $ (74,874) $ (50,122)
Basic earnings (loss) per common share $ 0.20 $ (0.08) $ (0.04) $ (0.11) $ (3.06) $ (0.03) $ (0.14) $ (0.17)   $ (0.03) $ (3.18) $ (2.40)
Earnings (loss) per common share assuming dilution $ 0.20 $ (0.08) $ (0.04) $ (0.11) $ (3.06) $ (0.03) $ (0.14) $ (0.17)   $ (0.03) $ (3.30) $ (2.40)
[1] Includes impairment charge for the company's IPR&D asset of $92,369,000